Industry News
Biotechnology Industry News
Eli Lilly has linked its amylin…
Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to prepare to enter phase 3 next month.
Evommune is heading to the New…
Evommune is heading to the New York Stock Exchange this morning via a $150 million IPO that the inflammation biotech will use to fund a pair of clinical-stage candidates.
AstraZeneca has ended work on one…
AstraZeneca has ended work on one of its drugs for fatty liver disease after viewing disappointing data from a phase 2 study.
Dynavax is paying $30 million…
Dynavax is paying $30 million upfront for global rights to Vaxart’s investigational oral COVID-19 vaccine candidate, positioning the biotech to see phase 2b data before placing a bigger bet on the program.
Amid the rapidly unfolding saga…
Amid the rapidly unfolding saga revolving around Metsera, a judge has denied Pfizer’s request to block Novo Nordisk’s buyout bid for the biotech, Bloomberg reports.
In a letter to lawyers for Novo…
In a letter to lawyers for Novo and Metsera, an FTC official wrote that the proposed purchase of Metsera by the Danish pharma "may violate the procedural provisions" of the Hart-Scott-Rodino (HSR) Act.
Eli Lilly is inking a $100…
Eli Lilly is inking a $100 million-plus biobucks deal with Insilico Medicine in hopes of using AI to discover new drugs.
Novo Nordisk is winding down a…
Novo Nordisk is winding down a range of early-stage programs for liver disease, oncology and stem cells as part of the Danish Pharma’s ambitious restructuring.
Eli Lilly has pulled out of the…
Eli Lilly has pulled out of the central-nervous-system-focused portion of a $960 million biobucks deal centered on Rigel Pharmaceuticals’ receptor-interacting serine/threonine-protein kinase 1 inhibitors.
Novo Nordisk’s CEO won’t…
Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera but said the Big Pharma “feels this deal will be closed.
The FDA has rejected Biohaven’s…
The FDA has rejected Biohaven’s request for approval of a neurological disorder therapy, prompting the biopharma to reprioritize its pipeline.
Following a middling phase 3…
Following a middling phase 3 readout for gastric cancer candidate bemarituzumab, Amgen has stopped another trial of the molecule.
Less than two years after…
Less than two years after emerging, Arena BioWorks is shuttering, citing the “adverse impact of biotech macro conditions” as the reason for the sudden closure.
The…
The hypertrophic-cardiomyopathy-focused biotech is led by former HI-Bio founder and CEO Travis Murdoch, M.D., while Biogen's CEO Chris Viehbacher chairs the board of directors.
Protara is working to address…
Protara is working to address choline deficiency in patients who are dependent on parenteral nutrition and don’t have available treatment today.
Eli Lilly is doubling down on its…
Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that could net a subsidiary of the artificial intelligence drug discovery shop as much as $345
Pfizer has axed 11 programs…
Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage MASH combo.
Fueled by public-private…
Fueled by public-private partnerships, talent development, and cutting-edge research, Ohio is emerging as a powerhouse in biotech and healthcare innovation.
Questex has acquired The…
Questex has acquired The Conference Forum and Versalinx Global Events, two highly respected organizers known for convening the leaders shaping clinical innovation, competitive intelligence, market research and the future of drug delivery.
As deal-making rebounds in a…
As deal-making rebounds in a volatile year, Waterhouse Brands urges biotech firms to prioritize storytelling, credibility and long-term strategy.